John Heise
Adolescent Medicine · Chattanooga, TNNPI 1962405787
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 52 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 8.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $408 and has fallen 84.3% since, to $64 in 2025.
Across 52 payments — averaging $21.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Azurity Pharmaceuticals, Inc.$95
- Ascendis Pharma Endocrinology Inc$93
- Endo Pharmaceuticals Inc.$90
- Greenwich Biosciences, Inc.$87
- Abbott$81
- Mallinckrodt Hospital Products Inc.$56
- plus $600 from 24 others
What the payments were for
- Food & beverage$1,103100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Azurity Pharmaceuticals, Inc. | 5 | $95 |
| Ascendis Pharma Endocrinology Inc | 5 | $93 |
| Endo Pharmaceuticals Inc. | 5 | $90 |
| Greenwich Biosciences, Inc. | 1 | $87 |
| Abbott | 4 | $81 |
| Mallinckrodt Hospital Products Inc. | 2 | $56 |
| Zealand Pharma US, Inc. | 3 | $51 |
| Biomarin Pharmaceutical Inc. | 2 | $38 |
| Kyowa Kirin, Inc. | 2 | $35 |
| Xeris Pharmaceuticals, Inc. | 2 | $34 |
| AstraZeneca | 2 | $32 |
| ANI Pharmaceuticals, Inc. | 1 | $30 |
| Merck | 1 | $28 |
| Corium, LLC | 1 | $27 |
| Organon | 1 | $26 |
| Sanofi-aventis U.S. LLC | 1 | $25 |
| BETA Bionics, Inc. | 1 | $24 |
| Ipsen Biopharmaceuticals, Inc | 1 | $24 |
| Endo USA, Inc. | 1 | $23 |
| Verrica Pharmaceuticals Inc. | 1 | $22 |
| Sanofi Pasteur Inc. | 1 | $22 |
| BD | 1 | $22 |
| Tandem Diabetes Care, Inc. | 1 | $21 |
| Neurocrine Biosciences, Inc. | 1 | $20 |
| GSK | 1 | $19 |
| Insulet Corporation | 1 | $18 |
| Pfizer | 1 | $16 |
| Eton Pharmaceuticals, Inc. | 1 | $16 |
| Novo Nordisk | 1 | $15 |
| AbbVie | 1 | $13 |
How this compares
$1,103 in reported general payments places this provider in the 70th percentile of 34 adolescent medicine providers in Tennessee.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Montelukast Sodium | 13 | $56 |
Paid to pharmacies, not to this prescriber.
Other adolescent medicine in Chattanooga
- Martha BowdenMemphis$50K
- Ara HanissianCollierville$26K
- Alston WarrGermantown$7K
- Mary RomanoNashville$5K
- Lea LundHendersonville$3K
- Landon CombsGray$2K
- Stephen CombsGray$2K
- Catherine SipeSmyrna$2K
- Lloyd FranklinCookeville$1K
- Ashley RhodesMonteagle$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.